Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

380R-1

Sigma-Aldrich

Arginase-1 (SP156) Rabbit Monoclonal Antibody

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12352204
Nomenclature NACRES :
NA.41

Source biologique

rabbit

Niveau de qualité

100
500

Conjugué

unconjugated

Forme d'anticorps

culture supernatant

Type de produit anticorps

primary antibodies

Clone

SP156, monoclonal

Description

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forme

buffered aqueous solution

Espèces réactives

human

Conditionnement

vial of 0.1 mL concentrate (380R-14)
vial of 0.5 mL concentrate (380R-15)
bottle of 1.0 mL predilute (380R-17)
vial of 1.0 mL concentrate (380R-16)
bottle of 7.0 mL predilute (380R-18)

Fabricant/nom de marque

Cell Marque™

Technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

Isotype

IgG

Contrôle

hepatocellular carcinoma, normal liver

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Visualisation

cytoplasmic, nuclear

Informations sur le gène

human ... ARG1(383)

Description générale

Arginase is a key metalloenzyme of the urea cycle responsible for the hydrolysis of L-arginine to L-ornithine and urea. Two main isoforms exist, arginase-1 and arginase-2, encoded by different genes and with different tissue distributions. The arginase-1 isoform is a cytosolic protein that is produced by normal liver tissue and is typically expressed in hepatocellular carcinoma. Arginase-1 (SP156) is used as an immunohistochemical marker to aid in the identification of hepatocellular carcinoma.

Qualité


IVD
IVD
IVD
RUO

Liaison

Arginase-1 Positive Control Slides, Product No. 380S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Forme physique

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Notes préparatoires

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Autres remarques

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informations légales

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Benign and malignant tumors of the liver
Linda DF
Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas, 2nd ed., 1291-1325 (2009)
Alexandre Sherlley Casimiro Onofre et al.
Cancer, 111(4), 259-268 (2007-06-15)
Difficulties with cytologic diagnoses on fine-needle aspiration cytology (FNAC) of the liver can be overcome by the application of immunocytochemical panels applied on smears. The aim of the current study was to analyze the performance of a panel of monoclonal
R L Zimmerman et al.
Cancer, 93(4), 288-291 (2001-08-17)
Diagnosing liver tumors by fine-needle aspiration biopsy is safe and accurate. However, there are cases that prove diagnostically difficult. Traditionally, immunostains for alpha-fetoprotein and polyclonal carcinoembryonic antigen have been used to distinguish adenocarcinomas from hepatocellular carcinomas (HCCs). In poorly differentiated
Z W Zhu et al.
Gut, 48(4), 558-564 (2001-03-15)
Hepatocellular carcinoma (HCC) is a common malignant tumour worldwide, and its differential diagnosis from benign lesions of the liver is often difficult yet of great clinical importance. In the present study, we analysed whether glypican-3 is useful in differentiating between
H B el-Serag
Clinics in liver disease, 5(1), 87-107 (2001-02-24)
The epidemiology of hepatocellular carcinoma (HCC) is characterized by marked differences between genders, ethnic groups, and geographic regions. These variations are explained by the nature, frequency, and time of acquisition of the major risk factors for cirrhosis--namely hepatitis B virus
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique